###begin article-title 0
Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors
###end article-title 0
###begin p 1
Conceived and designed the experiments: KM BN. Performed the experiments: KM. Analyzed the data: KM MK SEK DG CBG. Contributed reagents/materials/analysis tools: SEK RB. Wrote the paper: KM BN. Performed histological scoring: MK DG CBG. Contributed suggestions/revisions to paper: MK SEK RB CBG PHW. Ethics acquisition: RB.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Tumor-infiltrating T cells are associated with survival in epithelial ovarian cancer (EOC), but their functional status is poorly understood, especially relative to the different risk categories and histological subtypes of EOC.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 330 338 <span type="species:ncbi:9606">patients</span>
Tissue microarrays containing high-grade serous, endometrioid, mucinous and clear cell tumors were analyzed immunohistochemically for the presence of lymphocytes, dendritic cells, neutrophils, macrophages, MHC class I and II, and various markers of activation and inflammation. In high-grade serous tumors from optimally debulked patients, positive associations were seen between intraepithelial cells expressing CD3, CD4, CD8, CD45RO, CD25, TIA-1, Granzyme B, FoxP3, CD20, and CD68, as well as expression of MHC class I and II by tumor cells. Disease-specific survival was positively associated with the markers CD8, CD3, FoxP3, TIA-1, CD20, MHC class I and class II. In other histological subtypes, immune infiltrates were less prevalent, and the only markers associated with survival were MHC class II (positive association in endometrioid cases) and myeloperoxidase (negative association in clear cell cases).
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
###xml 224 232 <span type="species:ncbi:9606">patients</span>
Host immune responses to EOC vary widely according to histological subtype and the extent of residual disease. TIA-1, FoxP3 and CD20 emerge as new positive prognostic factors in high-grade serous EOC from optimally debulked patients.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 510 513 510 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Ozols1">[1]</xref>
###xml 515 518 515 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-duBois1">[2]</xref>
###xml 680 683 680 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Holschneider1">[3]</xref>
###xml 685 688 685 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Ozols2">[4]</xref>
###xml 82 87 <span type="species:ncbi:9606">women</span>
###xml 323 331 <span type="species:ncbi:9606">patients</span>
Ovarian cancer is the most deadly gynecologic cancer, affecting more than 190,000 women worldwide each year (International Agency for Research on Cancer). Delayed diagnosis and the presence of widely disseminated disease account for the high mortality associated with the disease. Additionally, while a large percentage of patients initially respond well to cytoreductive surgery and standard chemotherapy, the disease usually recurs within 2-5 years as residual tumor cells develop resistance to chemotherapy [1], [2]. Although prognosis is often poor, numerous favorable prognostic indicators have been described, including early stage, low grade and optimal surgical debulking [3], [4].
###end p 9
###begin p 10
###xml 239 242 239 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Zhang1">[5]</xref>
###xml 243 246 243 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Gimotty1">[9]</xref>
###xml 322 326 322 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Sato1">[10]</xref>
###xml 327 331 327 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Han1">[17]</xref>
###xml 580 584 572 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Marth1">[18]</xref>
###xml 586 590 578 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Kusuda1">[19]</xref>
###xml 616 620 604 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Duncan1">[20]</xref>
###xml 659 663 647 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Zeimet1">[21]</xref>
###xml 671 675 659 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Akahiro1">[22]</xref>
###xml 687 691 671 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Bamias1">[23]</xref>
###xml 705 709 689 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Rolland1">[24]</xref>
###xml 710 714 694 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Leffers2">[26]</xref>
###xml 761 765 745 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Han1">[17]</xref>
Several recent studies have analyzed the influence of host immunity on disease prognosis. Tumor-infiltrating CD3+ T cells are strongly associated with favorable prognosis, specifically when CD3+ cells are localized within tumor epithelium [5]-[9]. These findings have been extended to the CD8+ T cell subset in particular [10]-[17], suggesting that cytotoxic T lymphocytes (CTLs) play an important role in the antitumor immune response. Accordingly, other factors associated with CTL responses are also positively associated with survival, including interferon-gamma (IFN- gamma) [18], [19], the IFN- gamma receptor [20], interferon regulatory factor (IRF)-1 [21], IL-18 [22], TNF-alpha [23], MHC class I [24]-[26], and MHC class I antigen processing machinery [17].
###end p 10
###begin p 11
###xml 188 192 188 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Sato1">[10]</xref>
###xml 194 198 194 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Wolf1">[27]</xref>
###xml 199 203 199 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Woo1">[29]</xref>
###xml 415 419 412 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Miyara1">[30]</xref>
###xml 421 425 418 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Piccirillo1">[31]</xref>
###xml 520 524 517 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Kryczek1">[32]</xref>
###xml 755 759 752 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Leffers1">[14]</xref>
###xml 818 822 815 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Salama1">[33]</xref>
###xml 836 840 833 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-deJong1">[34]</xref>
###xml 841 845 838 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Carreras1">[36]</xref>
###xml 954 958 951 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Erdman1">[37]</xref>
###xml 960 964 957 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Lund1">[38]</xref>
###xml 1169 1173 1166 1170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Mahnke1">[39]</xref>
###xml 1174 1178 1171 1175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Rasku1">[44]</xref>
###xml 1203 1207 1200 1204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Barnett1">[45]</xref>
###xml 863 869 <span type="species:ncbi:10090">murine</span>
###xml 1160 1168 <span type="species:ncbi:9606">patients</span>
###xml 1194 1202 <span type="species:ncbi:9606">patients</span>
In contrast to CD8+ T cells, several studies have indicated that tumor-infiltrating CD25+FoxP3+ T cells (referred to as regulatory T cells or Tregs) are associated with decreased survival [10], [27]-[29]. Tregs have the ability to suppress proliferation, cytokine production, and cytolytic activity of CD4+ and CD8+ T cells by mechanisms involving cell-to-cell contact and the release of cytokines such as TGF-beta [30], [31]. Tregs can also induce an immunosuppressive phenotype in other cell types such as macrophages [32]. Although Tregs have been associated with poor prognosis in many cancers, several exceptions have recently been reported. Leffers et. al. found that FoxP3+ infiltrates in advanced stage EOC were associated with increased survival [14]. Similar findings have been reported in colorectal cancer [33] and lymphoma [34]-[36]. Furthermore, in murine models, FoxP3+ cells can play a positive role in anti-tumor and anti-viral immunity [37], [38]. The precise role of regulatory T cells in cancer outcomes warrants further consideration given that several groups are attempting to enhance tumor immunity by depleting FoxP3+ Tregs from cancer patients [39]-[44], including EOC patients [45].
###end p 11
###begin p 12
###xml 268 272 268 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Wei1">[46]</xref>
###xml 274 278 274 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Zou1">[47]</xref>
###xml 414 418 414 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Curiel2">[48]</xref>
###xml 644 648 644 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Duluc1">[49]</xref>
###xml 650 654 650 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Hagemann1">[50]</xref>
###xml 656 660 656 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Loercher1">[51]</xref>
###xml 780 784 780 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Kryczek2">[52]</xref>
###xml 875 879 875 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Kryczek1">[32]</xref>
###xml 1039 1043 1039 1043 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Liu1">[13]</xref>
###xml 1045 1049 1045 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Denkert1">[53]</xref>
In addition to Tregs, other cell types reportedly play an immunosuppressive role in EOC. For example, plasmacytoid dendritic cells contribute to immunosuppression by promoting the development or recruitment of interleukin-10-producing CD4+ and CD8+ regulatory T cells [46], [47]. Myeloid dendritic cells (MDCs) impair T cell immunity by expressing B7-H1, a ligand for the inhibitory receptor PD-1 found on T cells [48]. Monocytes and macrophages in the EOC microenvironment can be polarized toward a so-called M2 phenotype, which is typified by the expression of IL-10, TGF-b and scavenger receptors and is thought to promote tumor progression [49], [50], [51]. Under the influence of IL-6 and IL-10, macrophages in EOC can also express B7-H4, which inhibits T cell proliferation [52]. Macrophages also produce CCL22, which promotes Treg recruitment to the tumor environment [32]. Finally, expression of the inflammatory mediator COX-2 in tumor epithelium has been associated with reduced lymphocyte infiltration and poor prognosis in EOC [13], [53].
###end p 12
###begin p 13
###xml 489 493 489 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Kobel1">[54]</xref>
###xml 991 998 <span type="species:ncbi:9606">patient</span>
With the advent of tumor tissue microarray (TMA) technology, a large number of retrospective studies have investigated the relationship between tumor-infiltrating immune cells and prognosis in EOC and other cancers. However, most studies focus on one or a few markers, such that associations between different immunological factors may be missed. Additionally most studies fail to address the different histological subtypes of EOC, which are now recognized to behave as distinct diseases [54]. As a result, there are inconsistencies and unresolved issues in the literature concerning the prognostic significance of different immune cell infiltrates. To address this, we analyzed several large series of EOC tumors, including high-grade serous, endometrioid, clear cell and mucinous subtypes, for the presence of various immune cell infiltrates and inflammatory markers. Our results reveal that high-grade serous tumors have a distinct immunological profile that is strongly associated with patient survival.
###end p 13
###begin title 14
Results
###end title 14
###begin title 15
Intraepithelial T cells and associated functional markers in high-grade serous EOC
###end title 15
###begin p 16
###xml 306 310 306 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Kobel1">[54]</xref>
###xml 312 316 312 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Gilks1">[55]</xref>
###xml 500 507 500 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006412-t001">Table 1</xref>
###xml 124 132 <span type="species:ncbi:9606">patients</span>
###xml 356 364 <span type="species:ncbi:9606">patients</span>
###xml 463 470 <span type="species:ncbi:9606">Patient</span>
We initially investigated the relationship between immune infiltrates and survival in a cohort of 199 high-grade serous EOC patients. We chose to first focus on high-grade serous cases, as the other histological subtypes exhibit distinct biological and clinical properties that are potentially confounding [54], [55]. This initial cohort was restricted to patients who had undergone optimal cytoreduction (i.e., without evidence of macroscopic residual disease). Patient characteristics are shown in Table 1.
###end p 16
###begin title 17
###xml 73 80 <span type="species:ncbi:9606">patient</span>
Clinical characteristics of the optimally debulked high-grade serous EOC patient cohort.
###end title 17
###begin p 18
There were no deaths due to causes other than ovarian cancer, therefore disease-specific and overall survival were equivalent.
###end p 18
###begin p 19
###xml 175 179 175 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Clarke1">[12]</xref>
###xml 725 734 725 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006412-g001">Fig. 1A&amp;B</xref>
###xml 840 847 840 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006412-t002">Table 2</xref>
The tumors in this initial cohort had been previously assessed by immunohistochemistry (IHC) for a variety of lymphocyte markers, including CD3, CD4, CD8, CD20 and Granzyme B [12]. Intraepithelial lymphocytes (i.e., lymphocytes within the epithelial component of the tumor) were scored as either present (i.e. one or more intraepithelial lymphocytes present in at least one of two 0.6 mm cores) or absent. We re-analyzed this data focusing exclusively on high-grade serous cases. We found that 83.2% (163/196) of evaluable high-grade serous tumors were positive for intraepithelial CD3+ T cells, whereas CD4+ and CD8+ intraepithelial cells were found in 53.4% (103/193) and 84.0% (163/194) of evaluable tumors, respectively (Fig. 1A&B and data not shown). CD4+ and CD8+ cellular infiltrates showed a strong positive association (p<0.0001). Table 2 shows statistical associations for these and all other markers studied in this initial cohort.
###end p 19
###begin title 20
Immunohistochemical analysis of high-grade serous EOC tumors showing infiltrates expressing markers of T cell differentiation and activation.
###end title 20
###begin p 21
(A) CD4, (B) CD8, (C) CD45RO, (D) OX40, (E) CD25, (F) TIA-1, (G) Granzyme B, and (H) FoxP3. 40X objective.
###end p 21
###begin title 22
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
p-values for Chi-square tests of associations between immunohistochemical markers in the optimally debulked high-grade serous EOC cohort.
###end title 22
###begin p 23
GrB  =  Granzyme B.
###end p 23
###begin p 24
MHC I  =  MHC class I.
###end p 24
###begin p 25
MHC II  =  MHC class II.
###end p 25
###begin p 26
MPO  =  myeloperoxidase.
###end p 26
###begin p 27
COX-2  =  Cyclooxygenase-2.
###end p 27
###begin p 28
###xml 248 252 248 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Brenchley1">[56]</xref>
###xml 254 258 254 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Weinberg1">[57]</xref>
###xml 443 452 443 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006412-g001">Fig. 1C&amp;E</xref>
###xml 544 551 544 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006412-g001">Fig. 1D</xref>
###xml 634 641 634 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006412-t002">Table 2</xref>
While the above markers indicate which lymphocyte subsets are present in tumors, they do not reveal their activation state. To address this issue, we analyzed tumors for expression of CD45RO, OX40 and CD25, which are expressed by activated T cells [56], [57]. Using the same scoring criteria as above, 70.6% (132/187) of tumors were positive for intraepithelial CD45RO+ cells, and 49.7% (96/193) were positive for intraepithelial CD25+ cells (Fig. 1C&E). By contrast, only 7.0% (11/158) of tumors were positive for intraepithelial OX40+ cells (Fig. 1D). In pair-wise comparisons, CD45RO, CD25 and OX40 were all positively associated (Table 2). Moreover, CD45RO and CD25 were both associated with the presence of CD3+, CD4+ and CD8+ cells. OX40 showed a similar trend, but this did not reach statistical significance, likely due to the low number of positive cases.
###end p 28
###begin p 29
###xml 210 214 210 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Pipkin1">[58]</xref>
###xml 215 219 215 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Kanavaros1">[60]</xref>
###xml 307 314 307 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006412-g001">Fig. 1F</xref>
###xml 411 418 411 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006412-g001">Fig. 1G</xref>
###xml 757 764 757 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006412-t002">Table 2</xref>
To investigate the differentiation state of tumor-infiltrating T cells, tissues were analyzed for intraepithelial cells expressing TIA-1 and Granzyme B, which are markers of CD8+ cytotoxic T cells and NK cells [58]-[60]. A majority of tumors (66.5%, 127/191) were positive for intraepithelial TIA-1+ cells (Fig. 1F), and about half of tumors (45.6%, 88/193) were positive for intraepithelial Granzyme B+ cells (Fig. 1G). There was a highly significant association between TIA-1+ and Granzyme B+ cells (p<0.0001). Moreover, in pair-wise comparisons, TIA-1+ and Granzyme B+ cells were each associated with the activation markers CD45RO, CD25 and OX40. Finally, TIA-1+ and Granzyme B+ cells were each associated with the presence of CD3+, CD4+ and CD8+ cells (Table 2). To examine whether TIA-1 and Granzyme B expression could be due to the presence of NK or NKT cells, we examined tumors for the NK cell markers CD56 and CD57. For both markers, there were either few or no infiltrates at all within the tumor epithelium (data not shown), indicating that the TIA-1+ and Granzyme B+ infiltrates were most likely T cells.
###end p 29
###begin p 30
###xml 162 166 162 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Ziegler1">[61]</xref>
###xml 168 172 168 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Zou2">[62]</xref>
###xml 260 267 260 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006412-g001">Fig. 1H</xref>
###xml 485 489 485 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Sato1">[10]</xref>
###xml 491 495 491 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Leffers1">[14]</xref>
###xml 497 501 497 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Wolf1">[27]</xref>
###xml 503 507 503 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Curiel1">[28]</xref>
###xml 99 105 <span type="species:ncbi:9606">humans</span>
Finally, tumors were analyzed for the presence of intraepithelial cells expressing FoxP3, which in humans is a marker of regulatory T cells and activated T cells [61], [62]. About half of tumors (52.9%, 100/189) were positive for intraepithelial FoxP3+ cells (Fig. 1H). There was a strong association between FoxP3+ and CD25+ cells (p<0.0001), and FoxP3+ and CD25+ cells were each strongly associated with CD4+ cells (p<0.0001 for both markers). Thus, consistent with previous reports [10], [14], [27], [28], a significant proportion of tumors contained intraepithelial infiltrates with markers characteristic of Tregs (CD4+,CD25+, and FoxP3+).
###end p 30
###begin title 31
MHC class I and II in high-grade serous EOC
###end title 31
###begin p 32
###xml 411 420 411 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006412-g002">Fig. 2A&amp;B</xref>
###xml 692 699 692 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006412-t002">Table 2</xref>
We analyzed tumor cells for expression of MHC class I and II using a four-point scale (negative, focal [<10%], patchy [10-50%] or diffuse [>50%]). All evaluable tumors (185/185) expressed MHC class I to some degree (i.e., focal, patchy or diffuse), indicating they could theoretically present antigen to CD8+ T cells. For statistical analyses, only the highest category (diffuse, >50%) was considered positive (Fig. 2A&B). Using this threshold, 85.4% (158/185) of tumors were positive for MHC class I. MHC class I was positively associated with all three T cell subsets (CD3, CD4, and CD8), the activation markers CD45RO and CD25, and the differentiation markers TIA-1, Granzyme B and FoxP3 (Table 2).
###end p 32
###begin title 33
Immunohistochemical analysis of high-grade serous EOC tumors showing (A,B) high and low expression of MHC class I, (C,D) high and low expression of MHC class II, and (E,F) high and low expression of COX-2.
###end title 33
###begin p 34
40X objective.
###end p 34
###begin p 35
###xml 298 308 298 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006412-g002">Fig. 2 C&amp;D</xref>
###xml 660 667 660 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006412-t002">Table 2</xref>
###xml 884 891 884 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006412-t002">Table 2</xref>
A large majority of tumors (86.5%, 166/192) expressed MHC class II to some degree (i.e., focal, patchy or diffuse), indicating they could theoretically present antigen to CD4+ T cells. As with MHC class I, only the highest category (diffuse, >50%) was considered positive for statistical analyses (Fig. 2 C&D). Using this threshold, 41.1% (79/192) of tumors were positive for MHC class II. MHC class II was strongly associated with MHC class I (p<0.0001). Accordingly, MHC class II was positively associated with all three T cell subsets (CD3, CD4, and CD8), the activation markers CD45RO and CD25, and the differentiation markers TIA-1, Granzyme B and FoxP3 (Table 2). Similar to the results for MHC class I, the expression of MHC class II in tumor epithelium was positively associated with various T cell markers, including CD3, CD4, CD8, CD45RO, TIA-1, Granzyme B, CD25 and FoxP3 (Table 2).
###end p 35
###begin title 36
Intraepithelial B cells in high-grade serous EOC
###end title 36
###begin p 37
###xml 128 132 128 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Edwards1">[63]</xref>
###xml 212 219 212 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006412-g003">Fig. 3A</xref>
###xml 442 449 442 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006412-t002">Table 2</xref>
Tissues were stained with an antibody to CD20, which is expressed by B cells from the naive to memory stages of differentiation [63]. Intraepithelial CD20+ cells were found in 41.9% (83/198) of evaluable tumors (Fig. 3A). CD20+ infiltrates were strongly associated with all three T cell subsets (CD3, CD4, and CD8); the activation markers CD45RO and CD25; the differentiation markers TIA-1, Granzyme B and FoxP3; and both MHC class I and II (Table 2).
###end p 37
###begin title 38
Immunohistochemical analysis of high-grade serous EOC tumors showing infiltrates expressing (A) CD20 (B cells), (B) CD1a (immature DCs), (C) Myeloperoxidase (granulocytes), and (D) CD68 (macrophages).
###end title 38
###begin p 39
40X objective.
###end p 39
###begin title 40
Intraepithelial dendritic cells, granulocytes and macrophages in high-grade serous EOC
###end title 40
###begin p 41
###xml 199 206 199 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006412-g003">Fig. 3B</xref>
###xml 419 426 419 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006412-t002">Table 2</xref>
Tumors were analyzed for the presence of immature and mature dendritic cells by staining for CD1a and CD208, respectively. A minority of tumors (13.4%, 23/172) contained intraepithelial CD1a+ cells (Fig. 3B). No significant association with any of the intraepithelial lymphocyte markers (CD3, CD8 or CD20), activation markers (CD45RO or CD25), differentiation markers (TIA-1, Granzyme B or FoxP3) or MHC class I or II (Table 2) was seen, potentially due to the low number of CD1a+ cells. In contrast to CD1a, none of the tumors scored positive for intraepithelial CD208+ cells. Parallel analysis of tonsil tissue revealed the presence of many CD208+ cells, thereby validating the IHC procedure.
###end p 41
###begin p 42
###xml 108 115 108 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006412-g003">Fig. 3D</xref>
###xml 311 318 311 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006412-t002">Table 2</xref>
###xml 485 492 485 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006412-g003">Fig. 3C</xref>
About half of tumors (54.7%, 87/159) contained intraepithelial cells expressing the macrophage marker CD68 (Fig. 3D). CD68 was positively associated with several lymphocyte markers (CD3, CD8 and CD20), activation markers (CD45RO and CD25), differentiation markers (TIA-1, Granzyme B and FoxP3) and MHC class I (Table 2). To assess the presence of granulocytes, the TMA was stained for myeloperoxidase. Twenty four percent (37/154) of tumors contained myeloperoxidase-expressing cells (Fig. 3C), however these showed no significant associations with other markers, with the exception of CD4 (p = 0.034).
###end p 42
###begin p 43
###xml 123 127 123 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Denkert1">[53]</xref>
###xml 300 309 300 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006412-g002">Fig. 2E&amp;F</xref>
###xml 474 478 474 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Liu1">[13]</xref>
###xml 480 484 480 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Ahmadi1">[64]</xref>
###xml 486 490 486 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Lang1">[65]</xref>
###xml 593 600 593 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006412-t002">Table 2</xref>
The COX-2 enzyme has been associated with inferior survival in EOC when expressed in the epithelial component of the tumor [53]. Therefore, tumors were scored for expression of COX-2 in the epithelial component using a four-point scale (negative, equivocal [0-1%], patchy [1-50%] or diffuse [>50%]) (Fig. 2E&F). Two-thirds of tumors (66.5%, 111/167) were positive for COX-2 (i.e., patchy or diffuse staining). In contrast to reports in ovarian, cervical, and other cancers, [13], [64], [65], the expression of COX-2 was not significantly associated with any of the immune infiltrates studied (Table 2).
###end p 43
###begin title 44
###xml 44 51 <span type="species:ncbi:9606">patient</span>
Associations between immune infiltrates and patient survival in high-grade serous EOC
###end title 44
###begin p 45
###xml 164 167 164 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Zhang1">[5]</xref>
###xml 168 171 168 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Tomsova1">[7]</xref>
###xml 173 177 173 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Sato1">[10]</xref>
###xml 178 182 178 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Han1">[17]</xref>
###xml 293 302 293 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006412-g004">Fig. 4A&amp;B</xref>
###xml 414 421 414 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006412-g004">Fig. 4C</xref>
Kaplan-Meier analysis was performed to assess the association between various immune infiltrates and disease-specific survival (DSS). Consistent with prior reports [5]-[7], [10]-[17], intraepithelial CD3+ and CD8+ cells were associated with increased DSS (p = 0.0009 and 0.0008 respectively) (Fig. 4A&B). Intraepithelial CD4+ cells showed a trend towards increased DSS, but this was not statistically significant (Fig. 4C). The NK cell markers CD56 and CD57 showed no association with DSS (data not shown).
###end p 45
###begin title 46
Immune infiltrates and survival in ovarian cancer.
###end title 46
###begin p 47
###xml 58 66 <span type="species:ncbi:9606">patients</span>
###xml 267 275 <span type="species:ncbi:9606">patients</span>
Kaplan-Meier curves showing disease-specific survival for patients scored as positive or negative for (A) CD3, (B) CD8, (C) CD4, (D) FoxP3, (E) CD20, (F) CD68, (G) TIA-1, (H) Granzyme B, (I) MHC Class I and (J) MHC Class II. Data were derived from optimally debulked patients with high-grade serous EOC.
###end p 47
###begin p 48
###xml 91 98 91 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006412-g004">Fig. 4E</xref>
Intriguingly, intraepithelial CD20+ cells were associated with increased DSS (p = 0.0033) (Fig. 4E). Furthermore, the combination of CD8+ and CD20+ infiltrates was associated with significantly increased DSS over tumors that contained CD8+ infiltrates but not CD20+ infiltrates (median 4432 days vs. 2279 days, p = 0.0115) (data not shown).
###end p 48
###begin p 49
###xml 249 256 249 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006412-g004">Fig. 4F</xref>
In contrast to lymphocyte markers, the dendritic cell marker CD1a showed no association with DSS, possibly due to the low number of tumors containing CD1a+ cells. Likewise, the markers CD68, COX-2 and myeloperoxidase showed no association with DSS (Fig. 4F and data not shown).
###end p 49
###begin p 50
###xml 290 302 290 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006412-g004">Fig. 4G,I,&amp;J</xref>
###xml 596 603 596 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006412-g004">Fig. 4H</xref>
Given the association between CD8+ T cells and DSS, we evaluated other canonical features of active CTL responses. DSS was positively associated with intraepithelial TIA-1+ cells (p = 0.0003), as well as expression of MHC class I and II by tumor cells (p = 0.0014 and 0.0026 respectively) (Fig. 4G,I,&J). Tumors that contained both CD8+ and TIA-1+ infiltrates were associated with increased DSS compared to CD8+ TIA-1-negative tumors (p = 0.0025). Several other T cell markers, including Granzyme B, CD45RO and CD25, showed trends toward increased DSS but did not reach statistical significance (Fig. 4H and data not shown). OX-40 showed no apparent trend or association with DSS, possibly due to low numbers of positive cases (data not shown).
###end p 50
###begin p 51
###xml 184 191 184 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006412-g004">Fig. 4D</xref>
In apparent contrast to reports that regulatory T cells are associated with poor prognosis, the presence of intraepithelial FoxP3+ cells was associated with increased DSS (p = 0.010) (Fig. 4D). Moreover, tumors that were triply positive for intraepithelial CD4+, FoxP3+ and CD25+ cells showed a trend towards increased survival, although this fell short of statistical significance (p = 0.059). Likewise, tumors positive for both intraepithelial CD8+ and FoxP3+ cells showed a trend toward increased DSS compared to tumors that were positive for CD8+ cells but negative for FoxP3+ cells; however, this trend did not reach statistical significance (p = 0.052). Thus, by multiple analyses, tumor-infiltrating FoxP3+ cells showed a trend or statistically significant association with increased DSS.
###end p 51
###begin title 52
The association between immune infiltrates and survival is dependent on the extent of residual disease
###end title 52
###begin p 53
###xml 106 109 106 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Zhang1">[5]</xref>
###xml 111 115 111 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Shah1">[66]</xref>
###xml 52 60 <span type="species:ncbi:9606">patients</span>
###xml 253 261 <span type="species:ncbi:9606">patients</span>
###xml 518 525 <span type="species:ncbi:9606">patient</span>
###xml 534 542 <span type="species:ncbi:9606">patients</span>
###xml 850 858 <span type="species:ncbi:9606">patients</span>
T cell infiltrates are reportedly more prevalent in patients with optimal versus suboptimal cytoreduction [5], [66]. To investigate whether this was true for other lymphocyte markers, we analyzed an additional cohort of 220 high-grade serous cases from patients known to have macroscopic residual disease following primary cytoreductive surgery. We focused on CD8+ infiltrates, as well as the three novel prognostic markers from the preceding analysis (i.e., FoxP3, TIA-1 and CD20). Compared to the optimally debulked patient cohort, patients with macroscopic residual disease had a significantly lower prevalence of CD8+ (58.5%), FoxP3+ (20.2%), TIA-1+ (39.5%) and CD20+ (16.3%) infiltrates (p<0.0001 for all markers). In Kaplan-Meier analysis of these four markers, only CD8+ infiltrates had a significant association with survival (p = 0.0044) in patients with macroscopic residual disease (data not shown).
###end p 53
###begin title 54
The association between immune infiltrates and survival is dependent on histological subtype
###end title 54
###begin p 55
###xml 455 459 455 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Clarke1">[12]</xref>
###xml 446 454 <span type="species:ncbi:9606">patients</span>
The preceding results were based exclusively on high-grade serous EOC cases. To assess the association between immune infiltrates and DSS in other histological subtypes of EOC, we performed the same analyses using an additional 288 EOC tumors of the following histological subtypes: mucinous (n = 31), endometrioid (n = 125) and clear cell (n = 132). These additional tumor specimens were from a previously described cohort of optimally debulked patients [12].
###end p 55
###begin p 56
###xml 270 276 270 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006412-g005">Fig. 5</xref>
###xml 472 478 472 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006412-g005">Fig. 5</xref>
In general, immune infiltrates were less prevalent in the other histological subtypes compared to the high-grade serous cases discussed previously. This was true for all lymphocyte markers studied (i.e., CD3, CD8, CD4, CD45RO, CD25, FoxP3, TIA-1, Granzyme B, and CD20) (Fig. 5). The difference was most striking for the markers FoxP3, CD25 and CD20. After the high-grade serous cases, the next highest frequency of immune infiltrates was seen in the endometrioid subtype (Fig. 5).
###end p 56
###begin title 57
Prevalence of immune infiltrates and other markers across different histologic subtypes of EOC.
###end title 57
###begin p 58
###xml 272 280 <span type="species:ncbi:9606">patients</span>
Bars indicate the percentage of tumors scoring positive for intrapithelial cells expressing CD3, CD8, CD4, CD45RO, CD25, FoxP3, TIA-1, Granzyme B, CD20 and CD68. Expression of MHC class I and II by tumor epithelium is also shown. Data were derived from optimally debulked patients.
###end p 58
###begin p 59
We examined the association between immune infiltrates and DSS in the endometrioid and clear cell subtypes; the number of mucinous cases was too small to perform robust statistical analysis. For endometrioid cases, the only significant association found was between MHC class II expression and increased DSS (p = 0.039) (data not shown). For clear cell cases, the only significant association found was between the presence of myeloperoxidase-positive infiltrates and decreased DSS (p = 0.040, data not shown). Thus, the relationship between immune infiltrates and survival differs greatly between histological subtypes of EOC.
###end p 59
###begin title 60
Discussion
###end title 60
###begin p 61
###xml 148 152 148 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Clarke1">[12]</xref>
###xml 75 82 <span type="species:ncbi:9606">patient</span>
###xml 386 394 <span type="species:ncbi:9606">patients</span>
###xml 510 517 <span type="species:ncbi:9606">patient</span>
We systematically examined the relationship between immune infiltrates and patient survival in three large EOC series. In accord with Clarke et al. [12], we found that high-grade serous tumors have a distinct immunological profile compared to the endometrioid, clear cell and mucinous subtypes. Furthermore, we found that immune infiltrates were generally more prevalent in tumors from patients with optimal cytoreduction. FoxP3, TIA-1 and CD20 emerged as novel immunological markers associated with increased patient survival. Our results highlight the importance of histological subtype in the immunobiology of EOC, which may have important implications for the immunotherapy of this family of diseases.
###end p 61
###begin p 62
###xml 524 531 524 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006412-t002">Table 2</xref>
###xml 586 590 586 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Callahan1">[15]</xref>
###xml 591 595 591 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Han1">[17]</xref>
###xml 597 601 597 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Kooi1">[67]</xref>
###xml 839 843 839 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Clarke1">[12]</xref>
###xml 845 849 845 849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Shah1">[66]</xref>
###xml 1201 1204 1201 1204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Zhang1">[5]</xref>
###xml 1206 1210 1206 1210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Hamanishi1">[11]</xref>
###xml 1212 1216 1212 1216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Buckanovich1">[68]</xref>
###xml 1312 1315 1312 1315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Zhang1">[5]</xref>
###xml 1317 1321 1317 1321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Curiel1">[28]</xref>
###xml 1323 1327 1323 1327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Negus1">[69]</xref>
###xml 1462 1466 1462 1466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Clarke1">[12]</xref>
###xml 1468 1472 1468 1472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Tothill1">[70]</xref>
###xml 254 262 <span type="species:ncbi:9606">patients</span>
###xml 275 283 <span type="species:ncbi:9606">patients</span>
Intraepithelial lymphocytes (i.e., cells expressing CD3, CD4, CD8, FoxP3 or CD20) were more prevalent in high-grade serous cases, followed by endometrioid cases. Moreover, intraepithelial lymphocytes were more prevalent in tumors from optimally debulked patients compared to patients with macroscopic residual disease. A number of biological features of tumors appear to influence the density of lymphocytic infiltrates. (a) T cell infiltrates are positively associated with expression of MHC class I and II by tumor cells (Table 2), as well as MHC class I antigen processing machinery [15]-[17], [67], suggesting that antigen presentation may be an important determinant of T cell infiltration. (b) In accord with this notion, tumors with loss or mutation of the BRCA1 or p53 genes have an increased density of tumor-infiltrating T cells [12], [66]. This suggests that defective DNA repair and the ensuing genomic instability in tumors may lead to the generation of neo-antigens that trigger host T cell responses. (c) Signaling molecules also play a role, as the density of tumor-infiltrating T cells is negatively associated with expression of VEGF, B7-H1/PD-L1 and endothelin B receptor by tumors [5], [11], [68] and positively associated with expression of the chemokines CXCL9, CCL21, CCL22, CCL2 and CCL5 [5], [28], [69]. (d) Finally, two groups have reported gene expression profiles that correlate with the presence of tumor-infiltrating T cells in EOC [12], [70]. These latter studies confirm some of the above associations (e.g., MHC class I and II, beta 2 microglobulin, TAP1 and 2) and identify new factors associated with T cell infiltrates (e.g., IL-15, IL-32 and numerous interferon-induced genes). Presumably one or more of the above factors accounts for the observed enrichment of tumor-infiltrating lymphocytes in high-grade serous and optimally cytoreduced cases.
###end p 62
###begin p 63
###xml 125 129 125 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Sato1">[10]</xref>
###xml 130 134 130 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Han1">[17]</xref>
###xml 425 429 421 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Marth1">[18]</xref>
###xml 431 435 427 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Kusuda1">[19]</xref>
###xml 461 465 453 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Duncan1">[20]</xref>
###xml 535 539 527 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Rolland1">[24]</xref>
###xml 540 544 532 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Leffers2">[26]</xref>
###xml 587 591 579 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Han1">[17]</xref>
###xml 606 610 598 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Callahan1">[15]</xref>
###xml 612 616 604 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Matsushita1">[16]</xref>
###xml 628 632 620 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Zeimet1">[21]</xref>
###xml 640 644 632 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Akahiro1">[22]</xref>
###xml 659 663 647 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Bamias1">[23]</xref>
###xml 1046 1052 1034 1040 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006412-g004">Fig. 4</xref>
###xml 1120 1124 1108 1112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Kuroda1">[71]</xref>
###xml 1126 1130 1114 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Yakirevich1">[72]</xref>
###xml 1144 1148 1132 1136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Lyle1">[73]</xref>
###xml 1308 1312 1296 1300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Hasselblom1">[74]</xref>
###xml 1313 1317 1301 1305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Alvaro1">[78]</xref>
###xml 1464 1468 1452 1456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Anderson1">[79]</xref>
Although the association between intraepithelial CD8+ T cells and increased survival in EOC is a highly reproducible finding [10]-[17], relatively little is known about the functional phenotype of these CD8+ T cells. Several lines of evidence suggest a classic cytolytic response underlies favorable outcomes. For example, others have reported positive associations between survival and intratumoral expression of IFN- gamma [18], [19], the IFN- gamma receptor [20], as well as numerous interferon-responsive genes such as MHC class I [24]-[26], MHC class I antigen processing machinery [17], MHC class II [15], [16], and IRF-1 [21]. IL-18 [22] and TNF-alpha [23] also appear to be important components of the T cell response, as both cytokines are positively associated with survival. We examined two components of cytolytic granules, Granzyme B and TIA-1, both of which showed an association with CD8+ T cell infiltrates. Of these two markers, only TIA-1 showed a statistically significant association with survival in high-grade serous cases (Fig. 4). TIA-1+ cells have also been described in medullary breast cancer [71], [72] and melanoma [73], where they are associated with favorable prognostic features. By contrast, tumor-infiltrating TIA-1+ cells are associated with decreased survival in lymphoma [74]-[78]. Interestingly, TIA-1 is not simply a marker of cytolytic granules; it is an RNA binding protein involved in post-transcriptional mRNA regulation [79]. It remains to be determined whether the association between intraepithelial TIA-1+ cells and survival in EOC is due to the role of this protein in cytolytic granule function or mRNA regulation.
###end p 63
###begin p 64
###xml 88 92 88 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Sato1">[10]</xref>
###xml 94 98 94 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Wolf1">[27]</xref>
###xml 100 104 100 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Curiel1">[28]</xref>
###xml 164 168 164 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Leffers1">[14]</xref>
###xml 658 662 658 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Woo2">[80]</xref>
###xml 826 830 826 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Mizukami1">[81]</xref>
###xml 993 997 993 997 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Ahmadzadeh1">[82]</xref>
###xml 999 1003 999 1003 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Kryczek3">[83]</xref>
###xml 1056 1060 1056 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Karanikas1">[84]</xref>
###xml 1061 1065 1061 1065 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Ebert1">[86]</xref>
###xml 1070 1078 1070 1078 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1111 1115 1111 1115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Walker1">[87]</xref>
###xml 1116 1120 1116 1120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Imamichi1">[95]</xref>
###xml 1195 1199 1195 1199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Sato1">[10]</xref>
###xml 1201 1205 1201 1205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Curiel1">[28]</xref>
###xml 1369 1373 1369 1373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Roncador1">[89]</xref>
###xml 1375 1379 1375 1379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Roncarolo1">[96]</xref>
###xml 1497 1501 1497 1501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Kleinewietfeld1">[97]</xref>
###xml 1503 1507 1503 1507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Banham1">[98]</xref>
###xml 547 555 <span type="species:ncbi:9606">patients</span>
###xml 980 985 <span type="species:ncbi:9606">human</span>
Treg infiltrates have previously been associated with decreased survival in ovarian EOC [10], [27], [28]. However, in the present study and one other recent report [14], FoxP3+ infiltrates were associated with increased survival. These seemingly contradictory findings may be attributable to several factors. First, not all studies take into consideration the histological subtypes of EOC, or the extent of residual disease; in the present study, FoxP3+ cells were only associated with survival in high-grade serous tumors from optimally debulked patients. Second, a variety of antibodies have been used to detect FoxP3, which can lead to discordant results [80]. Third, different scoring criteria may be used. For example, the precise intratumoral location of Tregs is an important determinant of prognosis in gastric cancer [81]. Fourth, the molecular markers used to define Tregs differ between studies. Although FoxP3 is still regarded as the most reliable marker of Tregs in human cancer [82], [83], it can also be expressed by epithelial tumor cells [84]-[86] and in vitro activated CD4+ and CD8+ T cells [87]-[95]. For these reasons, some studies include CD25 as a second marker of Tregs [10], [28]. However, like FoxP3, CD25 is potentially expressed by effector T cells, so it is not clear that dual staining for FoxP3 and CD25 more accurately identifies Tregs [89], [96]. Other characteristics of Tregs include high expression of GITR and CTLA-4 and low expression of CD127 and CD49d and [97], [98], however these markers are technically difficult to assess on paraffin-embedded TMAs.
###end p 64
###begin p 65
###xml 429 434 429 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Hillen1">[103]</xref>
###xml 710 715 710 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Ayyoub1">[104]</xref>
###xml 716 721 716 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Koenen1">[106]</xref>
###xml 859 864 856 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Bettelli1">[107]</xref>
###xml 865 870 862 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Stockinger1">[109]</xref>
###xml 927 930 924 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Nelson1">[8]</xref>
###xml 986 991 983 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Kato1">[110]</xref>
###xml 992 997 989 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Leveque1">[112]</xref>
###xml 610 615 <span type="species:ncbi:9606">human</span>
These technical considerations notwithstanding, there is mounting evidence that tumor-infiltrating FoxP3+ cells are associated with a favorable prognosis in EOC, colorectal cancer, head and neck cancer, and lymphoma [14,33,-36,99-102]. How might FoxP3+ T cells promote favorable outcomes? In the present study, FoxP3+ cells were strongly associated with other effector T cells, and similar results have been reported in melanoma [103]. Thus, FoxP3+ cells may simply be an indicator of a strong CD8+ T cell response, which might outweigh any immunosuppressive effects of FoxP3+ cells. Alternatively, subsets of human FoxP3+ T cells have recently been shown to have a pro-inflammatory, IL-17-producing phenotype [104]-[106]. Indeed, CD4+ T cells can be skewed toward this so-called Th17 phenotype by exposure to TGF-beta in combination with IL-6, IL-1 or IL-23 [107]-[109]. These factors are present in the EOC tumor environment [8], and accordingly, Th17 cells have been reported in EOC [110]-[112]. Thus, the association between FoxP3+ cells and increased survival could potentially reflect an underlying Th17-like anti-tumor response. Clearly, more work is required to determine the extent to which FoxP3+ T cells in EOC represent Tregs versus Th17 or other effector T cells.
###end p 65
###begin p 66
###xml 207 212 207 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Dong1">[113]</xref>
###xml 660 665 660 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Hansen1">[114]</xref>
###xml 667 672 667 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Hansen2">[115]</xref>
###xml 804 809 804 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Schmidt1">[116]</xref>
###xml 1020 1025 1020 1025 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Hansen1">[114]</xref>
###xml 1027 1032 1027 1032 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Hansen2">[115]</xref>
###xml 1034 1039 1034 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Wang2">[117]</xref>
###xml 1040 1045 1040 1045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Nzula1">[120]</xref>
###xml 1440 1445 1440 1445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-KurtJones1">[121]</xref>
###xml 1446 1451 1446 1451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Ronchese1">[131]</xref>
###xml 1845 1849 1845 1849 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Yakirevich1">[72]</xref>
###xml 1851 1856 1851 1856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Tamiolakis1">[132]</xref>
###xml 1857 1862 1857 1862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Nedergaard1">[134]</xref>
###xml 473 481 <span type="species:ncbi:9606">patients</span>
The observation that intraepithelial CD20+ infiltrates are associated with increased DSS is a novel finding in EOC. Dong et. al. reported that B cells in ascites were associated with shorter survival in EOC [113], however their study focused on B cells in peritoneal and pleural effusions collected after chemotherapy, which by definition constitutes a poor outcome cohort. Indeed, in the present study, intraepithelial CD20+ B cells showed no association with survival in patients with high-risk, suboptimally debulked disease. Tumor-infiltrating CD20+ B cells are a hallmark of medullary breast cancer and have been proposed to mediate a favorable prognosis [114], [115]. Moreover, the presence of a B cell transcriptional signature in node-negative breast cancer is associated with increased survival [116]. B cell infiltrates in breast cancer represent clonally expanded populations, express somatically hypermutated IgG molecules, and recognize target antigens such as ganglioside D3 and surface-translocated actin [114], [115], [117]-[120]. It is unclear how tumor-infiltrating B cells promote favorable outcomes in cancer. In theory, their actions could be mediated by secreted antibodies, which can promote the opsonization of tumor antigens, complement-mediated destruction of tumor cells, or antibody-dependent cellular cytotoxicity. Apart from producing antibodies, B cells can also present antigen to both CD4+ and CD8+ T cells [121]-[131]. In this regard, it is noteworthy that ovarian tumors show low numbers of CD1a+ dendritic cells; perhaps CD20+ B cells serve as alternative antigen presenting cells in the tumor environment. This latter idea fits well with the observed co-localization of tumor-infiltrating B cells and CD8+ T cells in EOC, as well as in medullary breast cancer, non-small cell lung cancer and cervical cancer [72], [132]-[134].
###end p 66
###begin p 67
###xml 93 98 93 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Bingle1">[135]</xref>
###xml 100 105 100 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Sica1">[136]</xref>
###xml 162 166 162 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Shah1">[66]</xref>
###xml 376 381 376 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Gottfried1">[137]</xref>
###xml 638 643 638 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Sica1">[136]</xref>
###xml 784 788 784 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Kryczek2">[52]</xref>
###xml 79 84 <span type="species:ncbi:9606">human</span>
The presence of macrophages has been associated with poor prognosis in various human cancers [135], [136]. However, in accord with a prior report by Shah et. al. [66], we found no association between CD68+ infiltrates and survival in EOC. Importantly, however, CD68 is not a perfect marker of macrophages, as it is also expressed by dendritic cells and some non-myeloid cells [137]. Furthermore, CD68 does not distinguish between macrophages polarized towards the pro-inflammatory (M1) or tumor-promoting (M2) phenotypes. M1 macrophages have the capacity to kill tumor cells, whereas M2 macrophages promote tissue repair and angiogenesis [136]. Similarly, an immunosuppressive subpopulation of macrophages has been described in EOC based on expression of the signaling molecule B7-H4 [52]. Thus, additional functional markers may be required to fully define the role of macrophages in the immunobiology of EOC.
###end p 67
###begin p 68
###xml 528 532 528 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Leffers1">[14]</xref>
###xml 323 331 <span type="species:ncbi:9606">patients</span>
###xml 612 620 <span type="species:ncbi:9606">patients</span>
While this study focused on the relationship between immune infiltrates and prognosis after standard treatments, the results may also inform the design of immunotherapies for EOC. First, our findings suggest that high-grade serous tumors may be especially sensitive to T cell responses. Second, our data indicates that, in patients with residual disease, the influence of T cells may be overwhelmed by other factors. Third, the positive association between intraepithelial FoxP3+ cells and survival reported here and previously [14] prompts a reconsideration of strategies to deplete regulatory T cells from EOC patients. And fourth, the association between intraepithelial CD20+ cells and survival suggests the humoral immune response may play an important role in anti-tumor immunity that could be exploited therapeutically in parallel with CD8+ T cell responses.
###end p 68
###begin title 69
Materials and Methods
###end title 69
###begin title 70
Study subjects
###end title 70
###begin p 71
###xml 667 674 667 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006412-t001">Table 1</xref>
###xml 247 252 <span type="species:ncbi:9606">women</span>
###xml 478 486 <span type="species:ncbi:9606">Patients</span>
###xml 557 565 <span type="species:ncbi:9606">patients</span>
###xml 856 864 <span type="species:ncbi:9606">Patients</span>
###xml 1054 1062 <span type="species:ncbi:9606">patients</span>
###xml 1144 1152 <span type="species:ncbi:9606">Patients</span>
All specimens and clinical data were obtained with informed written consent under protocols approved by the Research Ethics Board of the BC Cancer Agency and the University of British Columbia. The main cohort used for this study consisted of 199 women with high-grade serous ovarian cancer seen at the BC Cancer Agency from 1984 to 2000 (OvCaRe Ovarian Tumour Bank, Vancouver, BC, Canada). Tumor tissue was obtained at the time of primary surgery prior to any other treatment. Patients had no macroscopic residual disease following surgical debulking. All patients underwent standard treatment consisting of surgery followed by standard platinum-based chemotherapy. Table 1 shows the general clinical characteristics of the 199-case cohort. We also analyzed a second cohort of mucinous (n = 31), endometrioid (n = 125) and clear cell (n = 132) EOC cases. Patients in this cohort were also diagnosed from 1984 to 2000, were optimally cytoreduced, and received platinum-based chemotherapy. Finally, we analyzed a third cohort of 220 high-grade serous EOC patients categorized as extreme risk due to the presence of residual macroscopic disease. Patients in this cohort were treated from 1996 to 2000 and received platinum-based chemotherapy.
###end p 71
###begin title 72
Tumor specimens
###end title 72
###begin p 73
Tumor tissue was obtained during primary cytoreductive surgery, fixed in 10% neutral buffered formalin, processed using standard procedures and embedded in paraffin. A tissue microarray (TMA) was constructed by taking duplicate 0.6 mm cores from representative regions of each tumor block after review of hematoxylin- and eosin-stained sections by a pathologist. TMAs were assembled using a Pathology Devices tissue arrayer (Westminster, MD).
###end p 73
###begin title 74
Immunohistochemistry
###end title 74
###begin p 75
###xml 103 107 103 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006412-Clarke1">[12]</xref>
###xml 607 614 607 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006412-t003">Table 3</xref>
Immunohistochemistry for CD20, CD3, CD4, CD8 and Granzyme B was performed as described in Clarke et al.[12]. The remaining unstained slides were received at the Trev and Joyce Deeley Research Centre where immunohistochemistry was performed for CD45RO, TIA-1, FoxP3, CD25, OX-40, CD56, CD57, CD1a, CD208, myeloperoxidase, CD68, COX-2, MHC Class I and MHC Class II. Following deparaffinization, the slides were placed in a Ventana Discovery XT autostainer (Ventana, Tucson, AZ) for immunohistochemical staining. Ventana's standard CC1 protocol was used for antigen retrieval. Primary antibodies are listed in Table 3.
###end p 75
###begin title 76
Primary antibodies used for immunohistochemistry.
###end title 76
###begin p 77
TMAs were incubated with primary antibodies for 60 minutes at room temperature, and the appropriate cross-adsorbed, biotinylated secondary antibody (Jackson Immunoresearch, West Grove, PA) was applied for 32 minutes. Bound antibodies were detected using the DABMap kit (Ventana), counterstained with hematoxylin (Ventana), and coverslipped manually with Cytoseal-60 (Richard Allan, Kalamazoo, MI).
###end p 77
###begin title 78
Histopathological analysis
###end title 78
###begin p 79
Immunostained TMAs were examined by a pathologist and scored using a variety of methods depending on the marker studied. For CD20, CD8, CD4, CD45RO, TIA-1, Granzyme B, CD25, OX40, CD1a, CD56, CD57, and myeloperoxidase, only cells residing within the epithelial compartment of the tumor were counted. FoxP3 was similarly scored within the epithelium but a stromal score was also obtained. Tumors were scored as 0 (no cells), 1 (1-5 cells), 2 (6-19 cells) or 3 (20+ cells); results were binarized as positive (IHC score 1, 2, or 3) or negative (IHC score 0). CD3 was scored as 0 (no cells present), 1 (cells present in stroma only), 2 (cells present in the epithelial compartment) or 3 (cells present in both the epithelial and stromal regions of the tumor); scores of 0 and 1 were reported as negative while a score of 2 or 3 was reported as positive. CD68 was scored as 0 (no cells present), 1 (luminal or stromal cells), 2 (scattered, <20 intraepithelial cells), or 3 (>20 intraepithelial cells), results were binarized in the same manner as CD3. COX-2 was scored as 0 (negative), 1 (equivocal, 0-1%), 2 (patchy, >1% to 50%) or 3 (diffuse, >50%) scores of 0 and 1 were reported as negative and scores of 2 or 3 were reported as positive. For MHC class I and II, samples were scored as 0 (negative), 1 (focal, <10%), 2 (patchy, 10-50%) or 3 (diffuse, >50%). Scores of 0, 1 or 2 were reported as negative and scores of 3 were reported as positive.
###end p 79
###begin title 80
Statistical analysis
###end title 80
###begin p 81
###xml 228 229 228 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Statistical analysis was performed using JMP statistical software (v7.0) (SAS Institute, Cary, NC). Univariate analysis was carried out using the Chi-Squared statistic. The log-rank test was used to compare Kaplan-Meier curves. p-values less than 0.05 were considered significant.
###end p 81
###begin p 82
We thank Jennifer Santos, Erika Mehl, Rob Grigor, and members of the Deeley Research Centre for assistance and advice.
###end p 82
###begin title 83
References
###end title 83
###begin article-title 84
###xml 88 96 <span type="species:ncbi:9606">patients</span>
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
###end article-title 84
###begin article-title 85
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.
###end article-title 85
###begin article-title 86
Ovarian cancer: epidemiology, biology, and prognostic factors.
###end article-title 86
###begin article-title 87
Management of advanced ovarian cancer consensus summary. Advanced Ovarian Cancer Consensus Faculty.
###end article-title 87
###begin article-title 88
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
###end article-title 88
###begin article-title 89
Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma.
###end article-title 89
###begin article-title 90
Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.
###end article-title 90
###begin article-title 91
The impact of T-cell immunity on ovarian cancer outcomes.
###end article-title 91
###begin article-title 92
Immune prognostic factors in ovarian cancer: lessons from translational research.
###end article-title 92
###begin article-title 93
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
###end article-title 93
###begin article-title 94
###xml 101 106 <span type="species:ncbi:9606">human</span>
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.
###end article-title 94
###begin article-title 95
Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss.
###end article-title 95
###begin article-title 96
Classification using hierarchical clustering of tumor-infiltrating immune cells identifies poor prognostic ovarian cancers with high levels of COX expression.
###end article-title 96
###begin article-title 97
Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer.
###end article-title 97
###begin article-title 98
Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer.
###end article-title 98
###begin article-title 99
Association of ovarian tumor epithelium coexpressing HLA-DR and CA-125 antigens with tumor infiltrating cytotoxic T lymphocytes.
###end article-title 99
###begin article-title 100
HLA Class I Antigen Processing Machinery Component Expression and Intratumoral T-Cell Infiltrate as Independent Prognostic Markers in Ovarian Carcinoma.
###end article-title 100
###begin article-title 101
Interferon-gamma expression is an independent prognostic factor in ovarian cancer.
###end article-title 101
###begin article-title 102
###xml 94 102 <span type="species:ncbi:9606">patients</span>
Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer.
###end article-title 102
###begin article-title 103
Loss of IFN gamma receptor is an independent prognostic factor in ovarian cancer.
###end article-title 103
###begin article-title 104
###xml 94 101 <span type="species:ncbi:9606">patient</span>
Intratumoral interferon regulatory factor (IRF)-1 but not IRF-2 is of relevance in predicting patient outcome in ovarian cancer.
###end article-title 104
###begin article-title 105
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Impact of serum interleukin-18 level as a prognostic indicator in patients with epithelial ovarian carcinoma.
###end article-title 105
###begin article-title 106
###xml 64 72 <span type="species:ncbi:9606">patients</span>
Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3(+)CD56(+) cells with platinum resistance.
###end article-title 106
###begin article-title 107
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human leukocyte antigen class I antigen expression is an independent prognostic factor in ovarian cancer.
###end article-title 107
###begin article-title 108
Class I histocompatibility antigen expression: a prognostic factor for aneuploid ovarian cancers.
###end article-title 108
###begin article-title 109
###xml 27 35 <span type="species:ncbi:9606">patients</span>
Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation.
###end article-title 109
###begin article-title 110
The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.
###end article-title 110
###begin article-title 111
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
###end article-title 111
###begin article-title 112
###xml 48 56 <span type="species:ncbi:9606">patients</span>
Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
###end article-title 112
###begin article-title 113
Natural regulatory T cells: mechanisms of suppression.
###end article-title 113
###begin article-title 114
Regulatory T cells in health and disease.
###end article-title 114
###begin article-title 115
###xml 52 59 <span type="species:ncbi:9606">patient</span>
###xml 71 76 <span type="species:ncbi:9606">human</span>
Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma.
###end article-title 115
###begin article-title 116
Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer.
###end article-title 116
###begin article-title 117
Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols.
###end article-title 117
###begin article-title 118
Roles of CD4+CD25(high) FOXP3+ Tregs in lymphomas and tumors are complex.
###end article-title 118
###begin article-title 119
High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma.
###end article-title 119
###begin article-title 120
###xml 84 88 <span type="species:ncbi:10090">mice</span>
CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice.
###end article-title 120
###begin article-title 121
Coordination of early protective immunity to viral infection by regulatory T cells.
###end article-title 121
###begin article-title 122
###xml 27 32 <span type="species:ncbi:9606">human</span>
Depletion of CD4(+)CD25(+) human regulatory T cells in vivo: Kinetics of Treg depletion and alterations in immune functions in vivo and in vitro.
###end article-title 122
###begin article-title 123
###xml 13 18 <span type="species:ncbi:9606">human</span>
Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.
###end article-title 123
###begin article-title 124
###xml 21 26 <span type="species:ncbi:9606">human</span>
Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration.
###end article-title 124
###begin article-title 125
###xml 57 65 <span type="species:ncbi:9606">patients</span>
Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.
###end article-title 125
###begin article-title 126
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.
###end article-title 126
###begin article-title 127
Transient T cell depletion causes regression of melanoma metastases.
###end article-title 127
###begin article-title 128
Regulatory T cells in ovarian cancer: biology and therapeutic potential.
###end article-title 128
###begin article-title 129
###xml 63 68 <span type="species:ncbi:9606">human</span>
Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma.
###end article-title 129
###begin article-title 130
###xml 28 33 <span type="species:ncbi:9606">human</span>
Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells.
###end article-title 130
###begin article-title 131
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.
###end article-title 131
###begin article-title 132
Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated-macrophage-like cells.
###end article-title 132
###begin article-title 133
Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype.
###end article-title 133
###begin article-title 134
###xml 97 105 <span type="species:ncbi:9606">patients</span>
Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells.
###end article-title 134
###begin article-title 135
###xml 73 78 <span type="species:ncbi:9606">human</span>
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma.
###end article-title 135
###begin article-title 136
###xml 70 75 <span type="species:ncbi:9606">human</span>
Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma.
###end article-title 136
###begin article-title 137
Ovarian carcinoma subtypes are different diseases: implications for biomarker studies.
###end article-title 137
###begin article-title 138
###xml 95 103 <span type="species:ncbi:9606">patients</span>
###xml 147 152 <span type="species:ncbi:9606">Human</span>
Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Human Pathology In press.
###end article-title 138
###begin article-title 139
###xml 23 28 <span type="species:ncbi:9606">human</span>
Expansion of activated human naive T-cells precedes effector function.
###end article-title 139
###begin article-title 140
OX40: targeted immunotherapy-implications for tempering autoimmunity and enhancing vaccines.
###end article-title 140
###begin article-title 141
Delivering the kiss of death: progress on understanding how perforin works.
###end article-title 141
###begin article-title 142
Identification and functional characterization of a TIA-1-related nucleolysin.
###end article-title 142
###begin article-title 143
Expression of cytotoxic proteins in peripheral T-cell and natural killer-cell (NK) lymphomas: association with extranodal site, NK or Tgammadelta phenotype, anaplastic morphology and CD30 expression.
###end article-title 143
###begin article-title 144
FOXP3: not just for regulatory T cells anymore.
###end article-title 144
###begin article-title 145
Regulatory T cells, tumour immunity and immunotherapy.
###end article-title 145
###begin article-title 146
B-cell targeting in rheumatoid arthritis and other autoimmune diseases.
###end article-title 146
###begin article-title 147
Prevention of both direct and cross-priming of antitumor CD8+ T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo.
###end article-title 147
###begin article-title 148
###xml 43 51 <span type="species:ncbi:9606">patients</span>
Immune restoration in head and neck cancer patients after in vivo COX-2 inhibition.
###end article-title 148
###begin article-title 149
###xml 146 151 <span type="species:ncbi:9606">women</span>
Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer.
###end article-title 149
###begin article-title 150
###xml 26 31 <span type="species:ncbi:9606">human</span>
HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2.
###end article-title 150
###begin article-title 151
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy.
###end article-title 151
###begin article-title 152
Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines.
###end article-title 152
###begin article-title 153
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
###end article-title 153
###begin article-title 154
Immunophenotype of lymphocytic infiltration in medullary carcinoma of the breast.
###end article-title 154
###begin article-title 155
Cytotoxic phenotype of tumor infiltrating lymphocytes in medullary carcinoma of the breast.
###end article-title 155
###begin article-title 156
TIA-1 positive tumor-infiltrating lymphocytes in nevi and melanomas.
###end article-title 156
###begin article-title 157
The number of tumour-infiltrating TIA-1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B-cell lymphoma.
###end article-title 157
###begin article-title 158
Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome.
###end article-title 158
###begin article-title 159
Prognostic significance of T-cell or cytotoxic molecules phenotype in classical Hodgkin's lymphoma: a clinicopathologic study.
###end article-title 159
###begin article-title 160
###xml 149 157 <span type="species:ncbi:9606">patients</span>
Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma: a quantitative tissue microarray study in a large retrospective cohort of 267 patients.
###end article-title 160
###begin article-title 161
Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells.
###end article-title 161
###begin article-title 162
Post-transcriptional regulation of proinflammatory proteins.
###end article-title 162
###begin article-title 163
FOXP3 immunohistochemistry on formalin-fixed paraffin-embedded tissue: poor correlation between different antibodies.
###end article-title 163
###begin article-title 164
Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer.
###end article-title 164
###begin article-title 165
FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions.
###end article-title 165
###begin article-title 166
###xml 36 41 <span type="species:ncbi:9606">human</span>
FOXP3 defines regulatory T cells in human tumor and autoimmune disease.
###end article-title 166
###begin article-title 167
###xml 20 25 <span type="species:ncbi:9606">human</span>
Foxp3 expression in human cancer cells.
###end article-title 167
###begin article-title 168
Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer.
###end article-title 168
###begin article-title 169
The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells.
###end article-title 169
###begin article-title 170
###xml 74 79 <span type="species:ncbi:9606">human</span>
Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells.
###end article-title 170
###begin article-title 171
###xml 76 82 <span type="species:ncbi:9606">humans</span>
Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans.
###end article-title 171
###begin article-title 172
###xml 40 45 <span type="species:ncbi:9606">human</span>
Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level.
###end article-title 172
###begin article-title 173
###xml 48 53 <span type="species:ncbi:9606">human</span>
Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development.
###end article-title 173
###begin article-title 174
###xml 39 44 <span type="species:ncbi:9606">human</span>
Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype.
###end article-title 174
###begin article-title 175
###xml 64 69 <span type="species:ncbi:9606">human</span>
Transient regulatory T-cells: a state attained by all activated human T-cells.
###end article-title 175
###begin article-title 176
###xml 33 38 <span type="species:ncbi:9606">human</span>
Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells.
###end article-title 176
###begin article-title 177
###xml 28 33 <span type="species:ncbi:9606">human</span>
Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production.
###end article-title 177
###begin article-title 178
IL-15 acts as a potent inducer of CD4(+)CD25(hi) cells expressing FOXP3.
###end article-title 178
###begin article-title 179
###xml 32 37 <span type="species:ncbi:9606">human</span>
Is FOXP3 a bona fide marker for human regulatory T cells?
###end article-title 179
###begin article-title 180
###xml 37 42 <span type="species:ncbi:9606">human</span>
CD49d provides access to "untouched" human Foxp3+ Treg free of contaminating effector cells.
###end article-title 180
###begin article-title 181
Cell-surface IL-7 receptor expression facilitates the purification of FOXP3(+) regulatory T cells.
###end article-title 181
###begin article-title 182
Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells.
###end article-title 182
###begin article-title 183
Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers.
###end article-title 183
###begin article-title 184
Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome.
###end article-title 184
###begin article-title 185
###xml 57 65 <span type="species:ncbi:9606">Patients</span>
Revisiting the Prognostic Value of Regulatory T Cells in Patients With Cancer.
###end article-title 185
###begin article-title 186
Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma.
###end article-title 186
###begin article-title 187
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the TH17 lineage-specific transcription factor ROR{gamma}t.
###end article-title 187
###begin article-title 188
###xml 63 69 <span type="species:ncbi:9606">humans</span>
Identification of IL-17-producing FOXP3+ regulatory T cells in humans.
###end article-title 188
###begin article-title 189
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells.
###end article-title 189
###begin article-title 190
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.
###end article-title 190
###begin article-title 191
TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells.
###end article-title 191
###begin article-title 192
Differentiation and function of Th17 T cells.
###end article-title 192
###begin article-title 193
Expression of IL-17 mRNA in ovarian cancer.
###end article-title 193
###begin article-title 194
###xml 29 34 <span type="species:ncbi:9606">human</span>
Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer.
###end article-title 194
###begin article-title 195
Interleukin 2-mediated conversion of ovarian cancer-associated CD4+ regulatory T cells into proinflammatory interleukin 17-producing helper T cells.
###end article-title 195
###begin article-title 196
NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma.
###end article-title 196
###begin article-title 197
Translocation of an intracellular antigen to the surface of medullary breast cancer cells early in apoptosis allows for an antigen-driven antibody response elicited by tumor-infiltrating B cells.
###end article-title 197
###begin article-title 198
The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells.
###end article-title 198
###begin article-title 199
The humoral immune system has a key prognostic impact in node-negative breast cancer.
###end article-title 199
###begin article-title 200
Focused antibody response in plasma cell-infiltrated non-medullary (NOS) breast cancers.
###end article-title 200
###begin article-title 201
Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast.
###end article-title 201
###begin article-title 202
###xml 51 56 <span type="species:ncbi:9606">human</span>
Novel ganglioside antigen identified by B cells in human medullary breast carcinomas: the proof of principle concerning the tumor-infiltrating B lymphocytes.
###end article-title 202
###begin article-title 203
###xml 104 109 <span type="species:ncbi:9606">human</span>
Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas.
###end article-title 203
###begin article-title 204
###xml 94 98 <span type="species:ncbi:10090">mice</span>
The role of antigen-presenting B cells in T cell priming in vivo. Studies of B cell-deficient mice.
###end article-title 204
###begin article-title 205
###xml 30 35 <span type="species:ncbi:9606">human</span>
B-lymphocyte contributions to human autoimmune disease.
###end article-title 205
###begin article-title 206
B lymphocytes can be competent antigen-presenting cells for priming CD4+ T cells to protein antigens in vivo.
###end article-title 206
###begin article-title 207
###xml 81 85 <span type="species:ncbi:10090">mice</span>
Defective induction of antigen-reactive proliferating T cells in B cell-deprived mice.
###end article-title 207
###begin article-title 208
T cell priming in vivo: a major role for B cells in presenting antigen to T cells in lymph nodes.
###end article-title 208
###begin article-title 209
The B cell is the initiating antigen-presenting cell in peripheral lymph nodes.
###end article-title 209
###begin article-title 210
###xml 26 30 <span type="species:ncbi:10090">mice</span>
Gene-targeted B-deficient mice reveal a critical role for B cells in the CD4 T cell response.
###end article-title 210
###begin article-title 211
A critical role for B cells in the development of memory CD4 cells.
###end article-title 211
###begin article-title 212
Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells.
###end article-title 212
###begin article-title 213
###xml 82 104 <span type="species:ncbi:1639">Listeria monocytogenes</span>
A specific role for B cells in the generation of CD8 T cell memory by recombinant Listeria monocytogenes.
###end article-title 213
###begin article-title 214
B lymphocytes in vivo fail to prime naive T cells but can stimulate antigen-experienced T lymphocytes.
###end article-title 214
###begin article-title 215
Immunophenotypic profile of tumor infiltrating lymphocytes in medullary carcinoma of the breast.
###end article-title 215
###begin article-title 216
Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer.
###end article-title 216
###begin article-title 217
###xml 55 63 <span type="species:ncbi:9606">patients</span>
A comparative study of the cellular immune response in patients with stage IB cervical squamous cell carcinoma. Low numbers of several immune cell subtypes are strongly associated with relapse of disease within 5 years.
###end article-title 217
###begin article-title 218
The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies.
###end article-title 218
###begin article-title 219
Macrophage polarization in tumour progression.
###end article-title 219
###begin article-title 220
Expression of CD68 in non-myeloid cell types.
###end article-title 220
###begin p 221
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 221
###begin p 222
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: The study was funded by grants from the British Columbia Cancer Foundation, Vancouver General Hospital Foundation, and U.S. Dept. of Defense (OC000018). None of the sponsors had any role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript.
###end p 222

